Pharmaceutical company, Stevanato Group, secure €200 million in funding for its drug solutions development
In a significant move for the Italian pharmaceutical sector, Stevanato Group has secured €200 million in financing from three major banks: BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM.
The funds, totaling €200 million, will be used to support the company's ongoing capital expenditure projects in Cisterna di Latina, Italy, and Fishers, Indiana, USA.
Marco Roberto Pessione, Head of Corporate Coverage at CDP, expressed pride in supporting Stevanato Group, a symbol of Italian industrial excellence, in its growth journey. Enrico Lemmo, Head of Corporate Banking North-East at Banco BPM, also expressed pride in supporting the growth plans of the leading Italian company in the pharmaceutical sector.
The financing aims to support Stevanato Group's capacity expansion efforts and the scaling of commercial production. BNL BNP Paribas, CDP, and Banco BPM each contributed to this strategic investment. BNL BNP Paribas provided €100 million, CDP committed €50 million, and Banco BPM contributed €50 million.
The funds will be primarily used to expand production capacity for pre-filled syringes and ready-to-use (RTU) cartridges at the Italian plant in Cisterna di Latina (CDP's €50 million contribution). Additionally, the financing will scale commercial production of pre-filled syringes in North America (Indiana) and Italy, along with completing the construction of device manufacturing facilities in Fishers (BNL BNP Paribas and Banco BPM contributions totaling €150 million).
Gianluca Mariani, Head of Industrial Manufacturing, Large Corporate Banking at BNL BNP Paribas, expressed support for Stevanato Group's investment in innovation, sustainability, and global expansion. All three banks believe in the value of companies that invest in research, quality, and sustainable development, and make a tangible contribution to the growth of the national economy.
This financing enables Stevanato Group to capitalize on robust customer demand and continue providing integrated solutions across the pharmaceutical value chain to help customers meet and exceed their development objectives. The company's executives highlighted that this investment reinforces Stevanato Group's commitment to innovation and competitiveness internationally while maintaining strong roots in Italy.
In summary, the €200 million financing is a strategic investment to bolster Stevanato Group's manufacturing capacity and infrastructure in Italy and North America, supporting its growth and expansion plans in key drug containment and delivery sectors. This reinforces the company’s commitment to innovation and competitiveness internationally while maintaining strong roots in Italy.
- The financing, a strategic move within the health-and-wellness and science industries, will aid Stevanato Group in expanding its production capabilities, particularly for pre-filled syringes and ready-to-use cartridges, thereby scaling commercial production in both Italy and North America.
- The financial support from three major banks – BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM – signifies an investment in Stevanato Group, a leading Italian company within the pharmaceutical sector, which aligns with the banks' belief in the value of companies that invest in research, quality, and sustainable development, ultimately contributing to the growth of the national economy and the finance industry.
